Hyloris Pharmaceuticals SA (LON:0AB6)

Market Cap	102.13M -34.4%
Revenue (ttm)	6.93M -18.7%
Net Income	-5.53M
EPS	-0.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Open	4.400
Previous Close	4.400
Day's Range	4.400 - 4.400
52-Week Range	4.380 - 8.220
Beta	0.64
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 24, 2026

About Hyloris Pharmaceuticals

Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias; and Valacyclovir oral suspension for the treatment of herpes virus infections. It also provides Ato...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 55
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0AB6

Financial Performance

In 2025, Hyloris Pharmaceuticals's revenue was 7.94 million, a decrease of -18.66% compared to the previous year's 9.76 million. Losses were -6.33 million, -0.13% less than in 2024.

Financial numbers in EUR

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 11, 2026

Data Sources Report a data error